Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 743 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Postmenopausal Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Older Men and Postmenopausal Women: A Randomized Controlled Study

NCT05031663
View directory record Official record
Conditions
Immune Response, Inflammation
Interventions
Almond group, Control Group
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

NCT06308614
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Estetrol, Placebo
Drug · Other
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women

NCT00540878
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (400 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Inspiratory Muscle Strength Training for Lowering Blood Pressure and Improving Endothelial Function in Postmenopausal Women: Comparison With "Standard of Care" Aerobic Exercise

NCT05000515
View directory record Official record
Conditions
Aging, Blood Pressure, Endothelial Dysfunction, Hypertension
Interventions
High-resistance inspiratory muscle strength training, Aerobic exercise
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
50 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Withdrawn Not applicable Interventional

The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence

NCT01123135
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Vaginal ERT, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

NCT00709540
View directory record Official record
Conditions
Osteoporosis
Interventions
ACE-011 or placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00217399
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
sorafenib tosylate, anastrozole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Dr. Tagliaferri's Menopause Formula

NCT01957306
View directory record Official record
Conditions
Hot Flashes
Interventions
Dr. Tagliaferri's Menopause Formula
Dietary Supplement
Lead sponsor
Herba Buena, Inc
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jul 21, 2026, 11:09 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

NCT07281547
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Biospecimen Collection, Low-Dose Aspirin, Patient Observation, Questionnaire Administration, Ultrasound Imaging
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Not applicable Interventional

Functional Snack Foods With Safflower Oil and Soy in Postmenopausal Women Having Metabolic Syndrome

NCT02199054
View directory record Official record
Conditions
Metabolic Syndrome, Overweight
Interventions
wheat-safflower oil pretzels, soy-safflower oil pretzels, control wheat pretzels
Other
Lead sponsor
Ohio State University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

NCT00803686
View directory record Official record
Conditions
Phase 1 Pharmacodynamic Study
Interventions
Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin K and Bone Turnover in Postmenopausal Women

NCT00062595
View directory record Official record
Conditions
Osteoporosis
Interventions
phylloquinone (K1), menatetranone (MK4)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2008 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

NCT00163137
View directory record Official record
Conditions
Osteoporosis
Interventions
lasofoxifene, raloxifene, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
48 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
72
States / cities
Albany, California • Berkeley, California • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

NCT00676663
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
Interventions
entinostat, exemestane, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Greenbrae, California • La Jolla, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jul 21, 2026, 11:09 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789
View directory record Official record
Conditions
Healthy
Interventions
bazedoxifene, bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 64 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

NCT02088684
View directory record Official record
Conditions
Breast Cancer
Interventions
LEE011, BYL719, fulvestrant, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 21, 2026, 11:09 AM EDT